Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VRC01 in Healthy Adults
NCT02165267Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2014
- Primary completion
- Feb 2016
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VRC01 in human immunodeficiency virus infection (HIV) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Assessment of local and systemic reactogenicity signs and symptoms, Measurements of laboratory measures of safety at Month 8 and 4 more. Started Aug 2014; status: completed.
02
Drugs
VRC01
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02165267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02165267.